Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Post by Kantenahon Jan 03, 2009 11:16am
490 Views
Post# 15679775

Corriente Buying Again

Corriente Buying Again
Looks like action is starting to pick-up on Cipher.  There has been some insider activity recently and now Corriente is buying again:
Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Unit Price
Jan 02/09 Dec 31/08 Corriente Master Fund, LP Direct Ownership Common Shares 10 - Acquisition in the public market 121,000 $0.441


Other recent insider activity includes:

Transaction                                                                                                                                            Holdings

Date              Insider Name       Nature of Transaction                Security               Price     Shares       Change      Closing Balance

Dec 05/08     Andrews, Larry  Acquisition in the public market Common Shares   0.483    1,500           23%              8,000

Nov 24/08    Andrews, Larry  Acquisition in the public market  Common Shares   0.441    4,000         >100%            6,500

Nov 21/08    Andrews, Larry  Acquisition in the public market  Common Shares   0.480    1,500         >100%            2,500

Nov 20/08    Andrews, Larry  Acquisition in the public market  Common Shares   0.480    1,000           n/a                 1,000

Nov 07/08    Corriente             Acquisition in the public market  Common Shares   0.450  42,000            1%         4,605,100

Nov 06/08    Macinnis, Donald  Grant of options                        Common Shares   0.450 180,000           n/a             180,000


Makes you wonder if something may be imminent regarding one or both of the drugs that are in the FDA pipeline.  Anyone have any thoughts?  I must say that I am surprised that there is not a little more action on this bullboard.  I'm new to Cipher and am still conducting my DD before deciding on a purchase.  If anyone has any data that they would like to share I would be very grateful.

-K

-K

Bullboard Posts